Site visit to Xelia Pharmaceutical
Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has completed the expansion of its new US$13m, Centralized Laboratory Services building at its Budapest manufacturing site. The expansion strengthens Xellia’s global anti-infective product capabilities with additional product stability and release testing expertise and capabilities.
The new 3,000m2, multi-story building accommodates state-of-the-art microbiology and chemical analytical laboratories, a product stability centre and administrative offices. It is conveniently located next to Xellia’s current Active Pharmaceutical Ingredient (APIs) manufacturing plant, which employs 250 people.
The new facilities will play a significant role in Xellia’s global operational strategy, strengthening its product release and stability testing services for APIs and Finished Dosage Form (FDF) produced across the Company’s other sites in the US, China and Denmark. The expansion has resulted in the creation of over 40 new roles within the quality team already and with recruitment still ongoing Xellia is aiming to increase the team at the Centralized Laboratory Services operation to around 80 employees by 2019.
The new facilities were opened today at a formal ceremony where Xellia executives welcomed local dignitaries including Mr. Peter Szijjártó, Minister of Foreign Affairs and, Mr. Zoltan Kovacs, Major of Kõbánya, a district of Budapest.
Carl-Åke Carlsson, Xellia’s CEO said; “We would like to thank Mr. Szijjártó, and, Mr. Kovacs, for joining us to celebrate the opening of our superb new facilities. In addition to further enhancing and adding new capabilities, we are continuing to expand our team. We are attracting highly-skilled employees, who have the expertise to help deliver quality assured anti-infective medicines to meet increasing demand from our global customers.”fd
“As anti-microbial drug resistance continues to pose a very real international threat, our work in the production of specialty anti-infectives is more important than ever. Many of the medicines that we manufacture are antibiotics of last resort, used to treat patients when all other treatments have failed. As a world-leading manufacturer we are committed to providing a high quality, secure and safe product supply.”